SpyGlass Pharma IPO Prices at $16, Raises $150 Million

SpyGlass Pharma Finalizes $150 Million IPO Pricing

SpyGlass Pharma Inc. has priced its initial public offering of 9,375,000 shares at $16.00 per share. The biopharmaceutical company expects to raise approximately $150 million in gross proceeds before deducting underwriting fees and other offering expenses.

Offering Details and Market Debut

The company's common stock is scheduled to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol "SGP". The offering includes a 30-day option for underwriters to purchase up to 1,406,250 additional shares at the IPO price. The offering's expected closing date is February 9, 2026.

Company Background and Focus

SpyGlass Pharma is a late-stage biopharmaceutical company focused on developing sustained drug delivery solutions for chronic eye conditions. Its platform is designed to work with approved medicines, including bimatoprost, to treat various ocular diseases. The joint book-running managers for the offering are Jefferies, Leerink Partners, Citigroup, and Stifel.

Summary

This IPO provides significant capital for SpyGlass Pharma to advance its clinical development programs. Investors will monitor the stock's performance following its Nasdaq debut as a key indicator of market confidence in its specialized drug delivery technology for ophthalmology.

FAQ

Q: What is SpyGlass Pharma's IPO price?
A: The IPO is priced at $16.00 per share.

Q: What is SpyGlass Pharma's stock ticker?
A: The company will trade on the Nasdaq Global Select Market under the ticker symbol "SGP".

Q: How much does SpyGlass Pharma expect to raise?
A: The company expects to raise approximately $150 million in gross proceeds.

Source: Investing.com